ArticleOncology letters2025
Retroperitoneal growth of high?grade serous ovarian carcinoma: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade serous ovarian carcinoma (HGSOC), an epithelial ovarian carcinoma, is primarily believed to originate from fallopian tube epithelial cells. This site of origin facilitates the dissemination of tumor cells to retroperitoneal organs or tissues, unrestricted by anatomical barriers, thereby promoting metastasis. The present report describes a rare case of HGSOC presenting with retroperitoneal involvement, and provides a comprehensive literature review on its pathogenesis, symptoms, diagnostic methods, treatment strategies and prognosis. The critical role of timely abdominal and pelvic imaging, along with tumor marker analysis, to evaluate patients with retroperitoneal tumors and nonspecific symptoms is emphasized. This approach aids in identifying the origin of retroperitoneal masses and facilitates the early diagnosis of metastatic HGSOC. Notably, an elevated serum CA125 level should raise suspicion of an ovarian malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.